BloodSurf 2016: Blood-Biomaterial Interactions

 描述(申请人提供)：生物材料诱导的血栓形成是所有用于治疗心血管疾病的与血液接触的医疗设备共同的头号临床问题，从相对简单的导管、球囊和支架到复杂的机械系统，如心室辅助装置(VAD)。虽然抗血栓和抗血小板药物，如肝素和氯吡格雷(Plavix)，通常用于抑制接受此类设备治疗的患者的生物材料诱导的血栓形成，但这些类型的药物从系统上抑制凝血，这可能导致其他临床上重大的出血相关并发症。抗血栓生物材料的开发将为心血管和血管疾病提供更有效的治疗，从而消除或至少大大减少使用系统性抗血栓治疗的需要。然而，对合成材料与血液接触后发生血栓反应的具体机制的了解有限，继续阻碍心血管和血管疾病的新临床设备和治疗方法的发展。解决这个问题需要来自不同领域的研究人员和从业者的努力--特别是，这需要生物学家、化学家、物理学家和工程师与临床从业者之间的密切互动。血浪2016研讨会(2016年9月13日至16日，马萨诸塞州韦尔斯利巴布森行政会议中心)的具体目的是将这些学科的专家以及对抗血栓生物材料的开发有共同兴趣的学生和博士后研究员聚集在一起，为期四天，沉浸在演讲和讨论中，讨论开发具有更好血液兼容性的医疗设备的关键需求和研究方向。认识到血小板在调节血液对生物材料的反应中的关键作用以及在止血和血栓形成领域与科学家和临床医生更紧密合作的必要性，本次研讨会将与第九届血小板国际研讨会联系在一起，该研讨会由哈佛医学院血小板研究研究主任兼医学教授Alan D.Michelson博士和耶路撒冷希伯来大学血液学教授David Varon博士协调。血小板国际研讨会将在2016年之后举行，包括一系列为期一天的联合会议。由于血浪2016是一次独特的会议，不属于每年正常安排的一系列专业会议，因此需要资金支持，以抵消我们16位受邀演讲者的出席费用，并提供8项学生/博士后旅行奖励(其中4项将拨给妇女、少数族裔和残疾人的支持)。 简介：生物材料引起的血栓形成是所有用于治疗心血管和血管疾病的接触血液的医疗设备共同面临的头号临床问题。血浪2016研讨会将汇集对改善与血液接触的医疗设备的血液相容性感兴趣的顶尖科学家、工程师和临床医生，进行为期四天的集中演讲和讨论。我们要求提供资金支持，以抵消我们邀请的16位演讲者的旅费，并为参加这次研讨会的学生和博士后研究员提供8项旅费奖励。

 DESCRIPTION (provided by applicant): Biomaterial-induced thrombus formation is the number one clinical problem common to all blood-contacting medical devices that are used in the treatment of cardiovascular and vascular disease, ranging from relatively simple catheters, balloons, and stents to complex mechanical systems such as ventricular assist devices (VADs). While antithrombotic and antiplatelet drugs, such as heparin and clopidogrel (Plavix), are commonly used to suppress biomaterial-induced thrombus formation for patients undergoing treatment with such devices, these types of drugs inhibit blood coagulation systemically, which can lead to other clinically significant bleeding-related complications. More effective treatments for cardiovascular and vascular disease would be provided from the development of thrombus-resistant biomaterials that would eliminate, or at least greatly reduce, the need for the use of systemic antithrombotic therapies. However, a limited understanding of the specific mechanisms underlying thrombotic reactions to synthetic materials following their contact with blood continues to hinder the development of new clinical devices and treatments for cardiovascular and vascular disorders. Addressing this problem requires the efforts of researchers and practitioners from diverse fields-in particular, this requires close interaction between biologists chemists, physicists, and engineers with clinical practitioners. The specific purpose of the BloodSurf 2016 Symposium (September 13-16, 2016, Babson Executive Conference Center, Wellesley, MA) is to bring together experts from these respective disciplines along with students and postdoctoral fellows who share a common interest in the development of thrombo-resistant biomaterials for four days immersed in presentations and discussions about the critical needs and research directions for the development of medical devices with improved blood compatibility. Recognizing the key role of platelets in mediating blood response to biomaterials and the need for closer integration with scientists and clinicians within the general hemostasis and thrombosis community, this symposium will be linked with the 9th Platelets International Symposium that is being coordinated by Dr. Alan D. Michelson, Director for Platelet Research Studies and Professor of Medicine, Harvard Medical School, and Dr. David Varon, Professor of Hematology, Hebrew University of Jerusalem. The Platelets International Symposium will follow BloodSurf 2016, including a one-day set of combined sessions. Because BloodSurf 2016 represents a unique meeting that falls outside of the normally scheduled set of professional conferences held each year, funding support is requested to offset the costs of attendance for our set of 16 invited speakers as well as providing eight student/postdoc travel awards (four of which will be set aside for the support of women, minorities, and persons with disabilities). Narrative: Biomaterial-induced thrombus formation is the number one clinical problem common to all blood-contacting medical devices that are used in the treatment of cardiovascular and vascular disease. The BloodSurf 2016 Symposium will bring together leading scientists, engineers, and clinicians interested in improving the blood compatibility of blood-contacting medical devices for four days of focused presentations and discussions. Funding support is requested to offset travel costs for our set of 16 invited speakers and to provide eight travel awards for students and postdoctoral fellows to attend this symposium.